By setting near term and long-term net-zero Green House Gas (GHG) reduction targets in line with the SBTi, this commitment reinforces Zentiva’s dedication to sustainability and aligns our decarbonisation roadmap with the European Union’s goal of becoming the first climate-neutral continent by 2050.These targets are grounded in the SBTi methodology, which ensures that corporate climate goals are aligned with the latest climate science and the objectives of the Paris Agreement. Unlike carbon neutrality claims that may rely on offsets, SBTi requires companies to prioritise deep emissions reductions of up to 90%, before addressing residual emissions through carbon removals. Overall Net-Zero Target: Zentiva commits to reach net-zero greenhouse gas emissions across the value chain by 2050.Near-Term Targets: Zentiva commits to reduce absolute scope 1 and 2 GHG emissions 63 % by 2034 from a 2021 base year and scope 3 GHG emissions 63 % by 2034 from a 2024 base year.Long-Term Targets: Zentiva commits to reduce absolute scope 1 and 2 GHG emissions 90 % by 2050 from a 2021 base year and scope 3 GHG emissions 90 % by 2050 from a 2024 base year. Zentiva’s climate targets are available on Target dashboard - Science Based Targets Initiative.The SBTi is globally recognised with a widely accepted framework for corporate climate targets. It provides a rigorous, science-based framework that ensures transparency, credibility, and alignment with international climate goals.Zentiva’s Sustainability Strategy is built around three core pillars: People, Partners, and Planet. This reflects a holistic commitment to responsible business practices and long-term value creation. By fulfilling our purpose of providing health and wellbeing for all generations, we acknowledge the impact we have on society and the environment. We strive to operate responsibly, minimising our environmental footprint while contributing to a healthier future.Zentiva’s sustainability efforts extend beyond decarbonisation to include measurable reductions in energy use, water consumption, and the amount of waste generated from its production, along with a focus on biodiversity restoration projects. Zentiva’s approach is guided by strong governance. For more information about Zentiva’s Sustainability Strategy, targets, and achievements for the business year 2024, please see our latest Sustainability Report, available at http://www.zentiva.com/our-impact/sustainability-report. For further information or queries please contact:

Zentiva Climate Targets Officially Validated by the  Science-Based Targets Initiative (SBTi)

2025-07-11-zentiva-climate-targets-officially-validated

Prague, July 09, 2025: Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for commercialization of Lupin&rsquo;s biosimilar, TNF alpha inhibitor medicine, across multiple markets globally. 
This strategic alliance aims to accelerate the availability of high-quality, cost-effective biosimilars to patients worldwide.  
Zentiva will oversee commercialization activities outside USA and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise.  Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories. Lupin will undertake commercialization in the remaining regions, including USA and Canada. 
Both parties will invest in the development of the new biosimilar. Lupin will receive an initial payment of USD 10 million upon execution of the agreement and total development and regulatory milestone payments up to USD 50 million.  The profits from the defined markets will be shared between the two companies.
The biosimilar product is a recombinant, humanized antibody Fab' fragment, with specificity for human tumor necrosis factor alpha (TNF&alpha;), conjugated to an approximately 40kDa polyethylene glycol.  It is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis and Crohn&rsquo;s disease. For further information or queries please contact:

Zentiva and Lupin Sign License and Supply Agreement for  TNF alpha inhibitor biosimilar medicine

2025-07-09-zentiva-and-lupin-sign-license

The conference was focused on “Building a Resilient Health Union: Security, Access and Competitiveness”. The agenda included critical topics such as the implementation of the EU Urban Wastewater Treatment Directive (UWWTD), the development of the Critical Medicines Act, the role of biotech and digitalisation, and the sustainability of procurement models and healthcare budgets. The discussions focused on how to strengthen Europe's manufacturing base, secure access to affordable medicines, and navigate the clean and digital transition while ensuring the access to medicines for people who depend on them every day.Zentiva’s CEO, Steffen Saltofte, joined a panel on the topic “Delivering access to medicines in the context of the Clean Transition and One Health” - advocating for a clean transition that does not compromise access to medicines. With the support of local associations, German Progenerika and Czech CAFF, he presented reality checks from Germany and the Czech Republic, two of Zentiva’s key markets.There is an urgent need to Pause – Repair – Relaunch, as the current implementation of the directive is unworkable for the generics industry.Zentiva highlighted the following three key messages:The current UWWTD implementation risks undermining medicine affordability, supply security, and long-term sustainability. Unrealistic assumptions and significantly underestimated cost assessments by the European Commission raise serious concerns about the continued availability of essential off-patent medicines across Europe.A better alternative exists – the Swiss model demonstrates how fair cost-sharing, phased implementation, and cross-sector collaboration can meet environmental goals without compromising patient care.We must safeguard the economic viability of medicines made in Europe. If environmental policies place disproportionate financial pressure on manufacturers, they risk driving production out of Europe - threatening both supply resilience and the EU’s ambition for strategic autonomy in healthcare. For further information or queries please contact:

Zentiva calls for Pause – Repair – Relaunch of the  Urban Wastewater Treatment Directive (UWWTD)

2025-06-30-zentiva-calls-for-pause

zentiva

daily

Header

Footer

Default

News

2022-09-30-Sustainability-report-2021

Acting today for a sustainable future. Discover Zentiva’s Sustainability Report 2021. Click here.

Latest news

Zentiva Climate Targets Officially Validated by the Science-Based Targets Initiative (SBTi)

Zentiva and Lupin Sign License and Supply Agreement for TNF alpha inhibitor biosimilar medicine

Zentiva calls for Pause – Repair – Relaunch of the Urban Wastewater Treatment Directive (UWWTD)

Explore

Stay tuned

Get in touch